文献速递流行病学与生物统计

随机临床试验方案的公开可及性:一项重复性元研究

Public availability of randomized clinical trial protocols: a repeated meta-research study.
PubMed 文献 · J Clin Epidemiol · 2025-07-02

该研究基于2016年瑞士、加拿大、德国和英国获批的347项随机临床试验,通过检索PubMed、Google Scholar、试验注册库和Google评估方案可及性。结果显示66%的试验有可公开获取的方案,高于2012年研究中的36%,改善主要来自企业赞助试验,非企业赞助试验方案可及性仍低。

要点

  • 2016年获批的347项随机临床试验中,66%(228/347)有可公开获取的方案。
  • 企业赞助试验方案可及性从2012年的34.6%升至2016年的83.4%,非企业赞助试验仅从38.1%升至46.4%。
  • 多中心试验方案可及性(77.7%)高于单中心试验(26.8%),样本量>500的试验可及性最高(88.3%)。

核心结论

  • 2016年获批的随机临床试验方案可及性较2012年提高,主要驱动力为企业赞助试验;应继续努力改善方案可及性,尤其是在非企业赞助的随机临床试验中。

研究设计与样本

  • 采用重复性元研究设计,纳入2016年在瑞士、加拿大、德国和英国获批的347项随机临床试验的代表性样本。
  • 通过检索PubMed、Google Scholar、试验注册库和Google,系统查找截至2024年6月可获取的同行评议方案发表、附于试验注册库的方案文件以及与结果发表共享的方案。
  • 使用多变量逻辑回归分析方案可及性与试验特征(样本量、药物vs非药物干预、多中心vs单中心、2016年vs2012年获批)的关联。

主要发现

  • 347项随机临床试验中,228项(66%)有可公开获取的方案。
  • 方案可及形式:43%(150/347)为试验注册库中的文件,26%(91/347)为结果发表的补充材料,23%(81/347)为同行评议发表。
  • 企业赞助试验方案可及性从2012年的34.6%升至2016年的83.4%;非企业赞助试验从38.1%升至46.4%。
  • 多中心试验方案可及性为77.7%(206/256),单中心试验为26.8%(22/82)。
  • 样本量>500的试验方案可及性为88.3%(68/77),100-500为68.6%(131/191),<100为36.7%(29/79)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Making protocols of randomized clinical trials (RCTs) publicly available is important for the trustworthiness and quality of medical research. In a previous study assessing 326 RCTs with ethical approval in 2012, only 36% had a publicly available protocol. We aimed to generate current evidence on the availability of RCT protocols and to evaluate changes over time. STUDY DESIGN AND SETTING: Using a representative sample of RCTs approved in 2016 in Switzerland, Canada, Germany, and the United Kingdom, we investigated the number of available protocols by searching PubMed, Google Scholar, trial registries, and Google. Up to June 2024, we systematically searched for (i) protocols available as peer-reviewed publications, (ii) protocols attached to trial registries, and (iii) protocols shared with result publications of RCTs. We used multivariable logistic regression to examine the association of protocol availability with trial characteristics such as sample size, drug vs nondrug interventions, multicenter vs single-center status, and RCT approval in 2016 vs 2012. RESULTS: Of the 347 included RCTs, 228 (66%) had an available protocol. Forty-three percent (150/347) of the protocols were available as files on trial registries, 26% (91/347) as supplementary material to result publication, and 23% (81/347) as peer-reviewed publications. Protocol availability improved over time in industry trials (83.4% in 2016 vs 34.6% in 2012). Protocol availability for nonindustry trials remained low (46.4% 2016 vs 38.1% 2012). Multicenter trials (206/256; 77.7% vs single-center trials 22/82; 26.8%) and larger sample size (>500 participants 68/77; 88.3%, 100-500 participants 131/191; 68.6%, <100 participants 29/79; 36.7%) showed higher protocol availability. CONCLUSION: The availability of protocols increased in RCTs approved in 2016 compared to RCTs from 2012. This was mainly driven by industry sponsored trials. Efforts to further improve protocol availability should be continued, especially in nonindustry sponsored RCTs.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Schönenberger CM, Chiaborelli M, Taji Heravi A, et al. Public availability of randomized clinical trial protocols: a repeated meta-research study. J Clin Epidemiol. 2025. PMID: 40513626. doi:10.1016/j.jclinepi.2025.111865

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。